Shanghai Pharma (2607.HK): Solid Q3 Results and Further integration of Cardinal October 30, 2018 742

Investment Summary
In 18Q3, core business continued to grow rapidly, given manufacturing and retail income grew at a high speed, and distribution segment delivered stable growth. We maintain the target price of HK$24, BUY rating. (Closing price at 26 Oct 2018)

About the author

Profile photo of Eurus Zhou

Eurus Zhou
Phillip Securities (HK)

Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!